Avinger (AVGR) Downgraded to Sell at Zacks Investment Research

Avinger (NASDAQ:AVGR) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Tuesday.

According to Zacks, “Avinger, Inc. is engaged in designing, manufacturing and selling image-guided, catheter-based systems to treat peripheral arterial disease. The company’s product consists of Lightbox imaging console, Wildcat, Kittycat, Ocelot, Ocelot PIXL, Ocelot MVRX and Juicebox. Avinger, Inc. is based in Redwood City, California. “

Shares of AVGR traded down $0.02 during trading hours on Tuesday, hitting $1.36. The stock had a trading volume of 138,007 shares, compared to its average volume of 1,012,526. Avinger has a 12 month low of $0.95 and a 12 month high of $25.20. The firm has a market capitalization of $16.17 million, a P/E ratio of -0.02 and a beta of 0.83.

Avinger (NASDAQ:AVGR) last issued its quarterly earnings data on Monday, August 13th. The medical device company reported ($0.98) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.50). The company had revenue of $2.06 million during the quarter. research analysts anticipate that Avinger will post -7.22 earnings per share for the current fiscal year.

About Avinger

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.

Read More: Buyback For Investors Defined

Get a free copy of the Zacks research report on Avinger (AVGR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Avinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avinger and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply